Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282968222> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4282968222 endingPage "2307" @default.
- W4282968222 startingPage "2307" @default.
- W4282968222 abstract "Abstract CDK4/6 inhibitors combined with endocrine therapy (ET) have shown clinical benefit in HR+, HER2- breast cancer. However, development of resistance highlights the need for treatment strategies to improve outcomes. To study resistance mechanisms, breast cancer cell lines were treated with CDK4/6i (abemaciclib or palbociclib) in combination with 4-OH-tamoxifen (tamoxifen) for 120-144h and sorted for resistant cells defined as geminin positive (GEM+), a marker of S/G2/M cell cycle accumulation. To confirm the resistant phenotype, cell lines were treated with tamoxifen plus the CDK4/6 inhibitor used to drive resistance. To understand if sequential CDK4/6i treatment is effective in controlling cell proliferation, resistant cells generated through treatment with palbociclib + tamoxifen or abemaciclib + tamoxifen were treated with abemaciclib + ET (fulvestrant or tamoxifen) or palbociclib + ET, respectively. Geminin/Ki67, annexin V and colony formation assays were performed to evaluate cell proliferation and viability. Molecular characterization by western blot and RNAseq analysis were utilized to provide insights into mechanisms of resistance and the effects of sequential treatment with CDK4/6i + ET. Cell lines resistant to palbociclib + tamoxifen subsequently treated with abemaciclib + ET showed decreased %GEM+ and colony formation ability, decreased Ki67 levels, and increased apoptosis. These effects were not observed in cell lines resistant to abemaciclib + tamoxifen following subsequent treatment with palbociclib + ET. Western blot analysis showed that palbociclib and abemaciclib-resistant cells had increased CDK6 and pERK levels, compared to control. Importantly, treatment of palbociclib-resistant cells with abemaciclib + ET decreased FOXM1, a key regulator of senescence and apoptosis. Cyclin A, a marker of mitosis, was also decreased, consistent with decreased %GEM+ subpopulation in palbociclib + ET resistant cells. These effects were not observed in abemaciclib-resistant cells treated with palbociclib + ET.In summary, our in vitro data provides mechanistic insights into resistance to combination CDK4/6i + tamoxifen and suggests the potential benefit of sequential treatment with abemaciclib + ET to overcome resistance in breast cancer. Citation Format: Elisabet Zapatero-Solana, Maria P. Ganado, Maria J. Ortiz-Ruiz, Cecilia Mur, Lacey Litchfield, Farhana Merzoug, Oscar Puig, Maria Jsoe Lallena. Sequential treatment with abemaciclib plus endocrine therapy inhibits cell proliferation and triggers apoptosis in cell lines resistant to CDK4/6i [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2307." @default.
- W4282968222 created "2022-06-17" @default.
- W4282968222 creator A5000134312 @default.
- W4282968222 creator A5020106101 @default.
- W4282968222 creator A5026868544 @default.
- W4282968222 creator A5062830770 @default.
- W4282968222 creator A5065774897 @default.
- W4282968222 creator A5071158182 @default.
- W4282968222 creator A5078869778 @default.
- W4282968222 creator A5081153905 @default.
- W4282968222 date "2022-06-15" @default.
- W4282968222 modified "2023-09-24" @default.
- W4282968222 title "Abstract 2307: Sequential treatment with abemaciclib plus endocrine therapy inhibits cell proliferation and triggers apoptosis in cell lines resistant to CDK4/6i" @default.
- W4282968222 doi "https://doi.org/10.1158/1538-7445.am2022-2307" @default.
- W4282968222 hasPublicationYear "2022" @default.
- W4282968222 type Work @default.
- W4282968222 citedByCount "0" @default.
- W4282968222 crossrefType "journal-article" @default.
- W4282968222 hasAuthorship W4282968222A5000134312 @default.
- W4282968222 hasAuthorship W4282968222A5020106101 @default.
- W4282968222 hasAuthorship W4282968222A5026868544 @default.
- W4282968222 hasAuthorship W4282968222A5062830770 @default.
- W4282968222 hasAuthorship W4282968222A5065774897 @default.
- W4282968222 hasAuthorship W4282968222A5071158182 @default.
- W4282968222 hasAuthorship W4282968222A5078869778 @default.
- W4282968222 hasAuthorship W4282968222A5081153905 @default.
- W4282968222 hasConcept C121608353 @default.
- W4282968222 hasConcept C124320809 @default.
- W4282968222 hasConcept C126322002 @default.
- W4282968222 hasConcept C143998085 @default.
- W4282968222 hasConcept C199649820 @default.
- W4282968222 hasConcept C2775930923 @default.
- W4282968222 hasConcept C2777176818 @default.
- W4282968222 hasConcept C2779744173 @default.
- W4282968222 hasConcept C2780482068 @default.
- W4282968222 hasConcept C29537977 @default.
- W4282968222 hasConcept C502942594 @default.
- W4282968222 hasConcept C51853150 @default.
- W4282968222 hasConcept C530470458 @default.
- W4282968222 hasConcept C54355233 @default.
- W4282968222 hasConcept C62112901 @default.
- W4282968222 hasConcept C71924100 @default.
- W4282968222 hasConcept C82495950 @default.
- W4282968222 hasConcept C86803240 @default.
- W4282968222 hasConceptScore W4282968222C121608353 @default.
- W4282968222 hasConceptScore W4282968222C124320809 @default.
- W4282968222 hasConceptScore W4282968222C126322002 @default.
- W4282968222 hasConceptScore W4282968222C143998085 @default.
- W4282968222 hasConceptScore W4282968222C199649820 @default.
- W4282968222 hasConceptScore W4282968222C2775930923 @default.
- W4282968222 hasConceptScore W4282968222C2777176818 @default.
- W4282968222 hasConceptScore W4282968222C2779744173 @default.
- W4282968222 hasConceptScore W4282968222C2780482068 @default.
- W4282968222 hasConceptScore W4282968222C29537977 @default.
- W4282968222 hasConceptScore W4282968222C502942594 @default.
- W4282968222 hasConceptScore W4282968222C51853150 @default.
- W4282968222 hasConceptScore W4282968222C530470458 @default.
- W4282968222 hasConceptScore W4282968222C54355233 @default.
- W4282968222 hasConceptScore W4282968222C62112901 @default.
- W4282968222 hasConceptScore W4282968222C71924100 @default.
- W4282968222 hasConceptScore W4282968222C82495950 @default.
- W4282968222 hasConceptScore W4282968222C86803240 @default.
- W4282968222 hasIssue "12_Supplement" @default.
- W4282968222 hasLocation W42829682221 @default.
- W4282968222 hasOpenAccess W4282968222 @default.
- W4282968222 hasPrimaryLocation W42829682221 @default.
- W4282968222 hasRelatedWork W1835371258 @default.
- W4282968222 hasRelatedWork W2148345265 @default.
- W4282968222 hasRelatedWork W2156119355 @default.
- W4282968222 hasRelatedWork W2341704440 @default.
- W4282968222 hasRelatedWork W2885649177 @default.
- W4282968222 hasRelatedWork W2937576470 @default.
- W4282968222 hasRelatedWork W2954222118 @default.
- W4282968222 hasRelatedWork W2994177419 @default.
- W4282968222 hasRelatedWork W3169821311 @default.
- W4282968222 hasRelatedWork W4282968222 @default.
- W4282968222 hasVolume "82" @default.
- W4282968222 isParatext "false" @default.
- W4282968222 isRetracted "false" @default.
- W4282968222 workType "article" @default.